ClinicalTrials.gg
CompletedNCT01959204Updated Jan 11, 2023Results posted

Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects

A Phase 4 interventional study of Oxycodone in Pain, sponsored by VistaPharm, Inc.. Completed at 9 sites in United States. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2023-01-11.

Sponsored by VistaPharm, Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
97
Allocation
Not applicable
Ages
1 Month to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing oxycodone in Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Oxycodone · Pain.

Enrollment
21st of 50
97 · median 67
Started
2013
with 2 others
Phase 4
18 of 50
none open now
Registered
22nd of 50
by date

Among the 50 studies testing oxycodone in Pain, this one is the 21st largest by enrollment, is one of 3 that started in 2013, is one of 18 in phase 4, and was the 22nd registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 50 studies testing oxycodone in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 1 Month to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing oxycodone in Pain, or all of them as a file.
02

Study summary

The objective of this study is to characterize the pharmacokinetics and to evaluate the safety of single and multiple doses of Oxycodone Oral Solution in pediatric and adolescent subjects for postoperative pain.

Read the detailed description

This is a Phase IV study to characterize the pharmacokinetics and to evaluate the safety of Oxycodone Oral Solution administered to pediatric and adolescent subjects for postoperative pain. It is an open label, multicenter study conducted at up to 10 sites. Subjects will be enrolled preoperatively up to 14 days before surgery with the expectation that they will require intravenous (IV) access after the surgery for at least 24 hours and postoperative analgesia with an opiate level medication. After dosing with Oxycodone Oral Solution (0.1 mg/kg for children ages 2 to 6, 0.08 mg/kg for ages 7 to 12, 0.07 mg/kg for ages 13 to 17, and a dose to be determined based on pharmacokinetic (PK) modeling from the interim analyses for subjects under age 2), subjects will be carefully monitored for safety. A total of 110 pediatric and adolescent male or female subjects will be enrolled, including a minimum of 20 subjects under age 2 (5 subjects ages 0 to \<2 months, 5 subjects ages 2 to \<6 months, and 10 subjects ages 6 months to \<2 years), 30 ages 2 to 6 years, 30 ages 7 to 12 years and 30 ages 13 to \<17 years. Subjects within each age group will be evenly distributed by age and gender.

An interim analysis will be run after 10 subjects ages 2 to 6 years, 10 ages 7 to 12 years and 10 ages 13 to \<17 years have completed the study. The interim analysis will include PK, pulse oximetry readings, vital sign measurements, adverse events (AEs) and concomitant medications. The dose of Oxycodone Oral Solution that the subjects ages 6 months to \<2 years will receive will be based on PK modeling from the interim analysis.

An additional interim analysis will be run after at least half of the subjects aged 6 months to \<2 years have completed the study. The interim analysis will include PK, pulse oximetry readings, vital sign measurements, AEs and concomitant medications. The dose of Oxycodone Oral Solution that the subjects ages 0 to \<2 months and 2 months to \<6 months will receive will be based on PK modeling from the interim analysis.

The study will consist of a Screening period within 14 days of surgery; a predose check-in (Day -1); a treatment period after surgery (Day 1, Time Zero); and an End of Study assessment. The total duration of the study, excluding Screening, will be approximately 1 full day.

Eligible subjects who provide assent (7 to \<17 years old) and whose parent(s) or legal guardian(s) provide consent as required will have study assessments performed at Screening. Following surgery, subjects will receive standard care, including parenteral analgesia with a nonoxycodone, nonoxymorphone medication that will not interfere with the measurement or metabolism of oxycodone. At this time (during Day -1), they will have a predose check-in to have eligibility confirmed.

After subjects ages 2 to \<17 have been postoperatively cleared to transition to oral pain medication, Oxycodone Oral Solution will be administered at Time Zero of Day 1 in place of the standard analgesic medication. The first 10 subjects in each of the 2 to 6, 7 to 12 and 13 to \<17 age groups, who will be included in the first interim analysis, will only receive 1 dose of Oxycodone Oral Solution. Subjects in these age groups enrolled in the study after the interim analysis is completed may receive additional doses every 4-6 hours as needed. If pain control is inadequate with Oxycodone Oral Solution, the investigator may administer an IV dose of ketorolac (0.5 mg/kg) every 6 hours or an IV dose of Morphine Sulfate (0.1 mg/kg) every 4 hours as rescue medication for breakthrough pain after dosing. Use of other rescue pain medication is permissible in accordance with hospital pain management guidelines or facilities standard of care. Any rescue medications used will be provided by the study site pharmacy.

After subjects under age 2 have been postoperatively cleared to transition to oral pain medication, they will receive a single dose of Oxycodone Oral Solution at Time Zero of Day 1 in place of the standard analgesic medication. The dose will be determined based on PK modeling from the interim analyses. If pain control is inadequate with Oxycodone Oral Solution, as indicated by a score of moderate to severe (4-10) on the FLACC, the subject will be given Fentanyl via Nurse-Controlled Analgesia (NCA). The Fentanyl will be provided by the study site pharmacy.

Subjects will undergo an End-of-Study assessment at least 24 hours after receiving the first dose of Oxycodone Oral Solution. At that time, if the study staff determines that it is safe to do so, subjects will be discharged from the study.

Safety will be assessed by monitoring AEs, clinical laboratory test results, vital sign measurements, temperature, pulse oximetry, and physical examination findings.

The Faces, Legs, Activity, Crying, Consolability Scale (FLACC) will be used to measure pain prior to and 20, 40, 60, 90, 120, 180, and 240 minutes after the dose of Oxycodone Oral Solution in subjects under age 2. The FLACC will also be administered prior to the subject receiving each dose of Fentanyl.

Serial blood samples for PK analysis will be collected for the determination of plasma concentrations of oxycodone and its metabolites (noroxycodone, oxymorphone and noroxymorphone) prior to the first dose (within 15 minutes of dosing); 5, 15, 30, and 60 minutes after dosing; and 2, 4, 6, 8, 12, and 24 hours after dosing. For subjects under age 2, serial blood samples for PK analysis will be collected prior to the first dose (within 15 minutes of dosing); 15, 30, and 60 minutes after dosing; and 2, 6, 12, and 24 hours after dosing.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • pharmacokinetics
  • safety
04

Who can participate

Ages eligible
1 Month to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is male or female \<17 years of age at the time of dosing.
  2. Subject 2 to \<17 years of age, be in at least the 25% for weight according to the Center for Disease Control pediatric growth charts and weighs at least 28 lb at the time of dosing with study drug.
  3. Is generally healthy as documented by medical history (except for the condition for which the procedure is being performed); physical examination (including, but not limited to, the cardiovascular, gastrointestinal, respiratory, and central nervous systems); vital sign assessments; 12-lead ; clinical laboratory assessments; and general observations. Has a negative serum pregnancy test at Screening and predose check in for females of .
  4. Is an outpatient for a surgical procedure and is expected to remain hospitalized for at least 24 hours after dosing with study drug.
  5. Is anticipated to have postsurgical pain requiring a parenteral analgesic regimen using a short-acting opioid analgesic and is anticipated to be switched to an oral opioid for at least 1 dose (according to institution standard of care).
  6. Has an indwelling access catheter for blood sampling.
  7. Agrees to comply with all protocol requirements. If not old enough, the legally responsible parent(s) or legal guardian(s) must agree to comply with all protocol requirements.
  8. Has been informed of the nature of the study and and assent (as appropriate) have been obtained from the legally responsible parent(s) or legal guardian(s) and the subject, respectively, in accordance with institutional review board requirements.

Exclusion criteria

Exclusion Criteria:

  1. Has the presence or history of a disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (except for the condition for which the procedure is being performed) as determined by the clinical investigator.
  2. Has any clinical laboratory test result outside the normal range.
  3. Has a positive test result for surface antigen, antibody, or antibody.
  4. Had a clinically significant illness, except for the condition for which the procedure is being performed, in the 28 days before dosing with study drug as determined by the clinical investigator.
  5. Is a lactating or breastfeeding female.
  6. Uses any medication known to be an inhibitor or inducer of within 14 days (for inhibitors such as the azole-antifungal agents voriconazole and ketoconazole, macrolide antibiotics such as erythromycin, and protease inhibitors such as ritonavir) or 28 days (for inducers such as rifampin, carbamazepine, and phenytoin) of dosing with study drug. Use of all other prescription medications, except required pre-op medications and , is prohibited within 3 days of dosing with study drug. Use of any over-the-counter medications (including herbal or dietary supplements and therapeutic doses of vitamins), except for required pre-op medications, is prohibited within 24 hours of dosing with study drug, with the exception of topical spermicide. Use of St. John's wort is prohibited from 28 days before dosing until 14 days after dosing. Standard daily dose multivitamins (nontherapeutic doses) may be taken until enrollment into the study but will be restricted during the study.
  7. Consumes alcohol-, caffeine-, or xanthine-containing products within 48 hours before dosing and during periods when blood samples are collected.
  8. Consumes grapefruit, grapefruit products, Seville oranges, or pomelo-containing products within 14 days of dosing. Fruit juices, with the exception of apple and grape, will be prohibited during the study.
  9. Is a smoker or has used nicotine or nicotine-containing products within 30 days of dosing.
  10. Has a history of alcohol or drug addiction or abuse within the last year.
  11. Subject 2 to \<17 years of age, has a positive urine test result for drugs of abuse (amphetamines, barbiturates, cannabinoids, cocaine metabolites, opiates, phencyclidine, and benzodiazepines) or alcohol at Screening (not required for subjects less than 2 years of age).
  12. Donated blood within 28 days or plasma within 14 days of dosing or plans to donate them within 4 weeks after completing the study.
  13. Has a history of relevant drug allergies, food allergies, or both (i.e., allergy to oxycodone, allergy to related drugs, or any significant food allergy that could interfere with the study).
  14. Is intolerant to direct venipuncture.
  15. Received an drug within 28 days of dosing.
  16. Has taken oxycodone or oxymorphone within the 48 hours before anticipated dosing with study drug.
  17. Is not suitable for entry into the study in the opinion of the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Other
    Active

    Open label pharmacokinetic study of oxycodone.

    Drug: Oxycodone

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax of Oxycodone Oral Solution.

    Cmax of Oxycodone over a 24 hour period.

    Time frame: 5, 15, 30, and 60 minutes post dose; and 2, 4, 6, 8, 12, and 24 hours post-dose.

Secondary outcomes

  1. Number of Participants With Adverse Events

    Patients will be monitored for adverse events such as change in blood pressure and lack of efficacy.

    Time frame: 48 hours

Other outcomes

  1. Tmax of Oxycodone Oral Solution.

    Tmax of Oxycodone Oral Solution over 24 hours in a pediatric population

    Time frame: 5, 15, 30, and 60 minutes post-dose; and 2, 4, 6, 8, 12, and 24 hours post-dose.

07

Results

Posted Jan 11, 2023

Participant flow

Participant flow — Overall Study
MilestoneOxycodone Oral Solution
Started97
Completed89
Not completed8

Outcome measures

PrimaryCmax of Oxycodone Oral Solution.

Cmax of Oxycodone over a 24 hour period.

Time frame:
5, 15, 30, and 60 minutes post dose; and 2, 4, 6, 8, 12, and 24 hours post-dose.
Reported as:
Mean · mg/kg
Cmax of Oxycodone Oral Solution.
mg/kgActive
Cmax of Oxycodone Oral Solution.5.92 ± .53
SecondaryNumber of Participants With Adverse Events

Patients will be monitored for adverse events such as change in blood pressure and lack of efficacy.

Time frame:
48 hours
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsActive
Number of Participants With Adverse Events20
Other pre-specifiedTmax of Oxycodone Oral Solution.

Tmax of Oxycodone Oral Solution over 24 hours in a pediatric population

Time frame:
5, 15, 30, and 60 minutes post-dose; and 2, 4, 6, 8, 12, and 24 hours post-dose.
Reported as:
Mean · Hours
Tmax of Oxycodone Oral Solution.
HoursActive
Tmax of Oxycodone Oral Solution.2.71 ± 2.67

Adverse events

Collected over Adverse events were collected over the course of the study (4 years). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active21/97 (21.6%)0/97 (0%)20/97 (20.6%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventActive
nauseaGastrointestinal disorders13/97
VomitingGastrointestinal disorders12/97
PruritusSkin and subcutaneous tissue disorders8/97
Liver function test increasedInvestigations2/97
AnaemiaBlood and lymphatic system disorders1/97
abdominal Pain UpperGastrointestinal disorders1/97
application site pruritusGeneral disorders1/97
ChillsGeneral disorders1/97
Injection site erythemaGeneral disorders1/97
PyrexiaGeneral disorders1/97

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Oxycodone Oral Solution
<=18 years97
Between 18 and 65 years0
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Oxycodone Oral Solution
Female45
Male52
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Oxycodone Oral Solution
Region of Enrollment
Region of Enrollment(Participants)Oxycodone Oral Solution
United States97
08

Study locations

9 sites
  • CHOC Children's Hospital
    Orange, California 92688, United States
  • Miami Children's Hospital
    Miami, Florida 33155, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • UNC at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • Vanderbilt Children 's Hospital
    Nashville, Tennessee 37232, United States
  • University of Texas Southwestern
    Dallas, Texas 33876, United States
  • Children's Medical center Dallas
    Dallas, Texas 75235, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Aug 2019 and a completion of Aug 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2023, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2013
First posted
Oct 9, 2013
Start
Oct 14, 2013
Primary completionActual
Aug 21, 2019
CompletionActual
Aug 21, 2019
Results first posted
Jan 11, 2023
Last update
Jan 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01959204
Lead sponsor
VistaPharm, Inc.
Responsible party
Sponsor
First posted
Oct 9, 2013
Start date
Oct 14, 2013
Primary completion
Aug 21, 2019
Completion
Aug 21, 2019
Results posted
Jan 11, 2023
Last update
Jan 11, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion